Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Divozilimab

Copy Product Info
😃Good
Catalog No. T77160Cas No. 2254061-60-2

Divozilimab (BCD-132), a humanized monoclonal antibody targeting CD20 (CD20), is utilized in multiple sclerosis research [1].

Divozilimab

Divozilimab

Copy Product Info
😃Good
Catalog No. T77160Cas No. 2254061-60-2
Divozilimab (BCD-132), a humanized monoclonal antibody targeting CD20 (CD20), is utilized in multiple sclerosis research [1].
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$2152-4 weeks2-4 weeks
5 mg$5632-4 weeks2-4 weeks
10 mg$8962-4 weeks2-4 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Divozilimab (BCD-132), a humanized monoclonal antibody targeting CD20 (CD20), is utilized in multiple sclerosis research [1].
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetCD20
Chemical Properties
Cas No.2254061-60-2
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storage-20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Divozilimab | purchase Divozilimab | Divozilimab cost | order Divozilimab